In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD.
The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 4–15 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study’s 10 mg/kg suramin arm displayed promising results in improving core symptoms of ASD, showcasing statistically significant improvements in the Clinical Global Impressions—Improvement (CGI-I) scale compared to the placebo group.
The study, registered with clinicaltrials.gov, represents a crucial advancement in exploring treatment options for ASD. PaxMedica’s unwavering commitment to pioneering research in neurological disorders is highlighted in the video release, demonstrating their dedication to enhancing the quality of life for individuals living with ASD.
The enlightening video can be viewed at https://ibn.fm/qKcGP, and the complete article is available for download at https://ibn.fm/Pc5ve.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in…
About 90% of men that undergo prostate cancer treatment, and almost 50% of men treated…
BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades.…
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies —…
The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk…
Aggressive repurchase of its own stock by Earth Science Tech, a growing holding company focused…